Saturday, November 8, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

inTest Shares: A Silver Lining Amidst a Sharp Decline

Robert Sasse by Robert Sasse
November 8, 2025
in Earnings, Semiconductors, Tech & Software
0
inTest Stock
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Following a disappointing quarterly earnings report, inTest Corporation’s stock experienced a significant sell-off. Although revenues fell short of expectations, prompting a drop of over 13% in the share price, a surprising surge in new orders provided a glimmer of hope for investors.

Order Intake Reveals Underlying Strength

Despite the negative headlines, a deeper look reveals a powerful counter-narrative. The company’s order intake exploded, soaring 34.2% year-over-year to reach $37.6 million. This marks the highest level seen since the second quarter of 2022. Even more impressive is the backlog, which climbed to a near-record $49.3 million.

Key order metrics include:
* Order Intake: Increased 34.2% compared to the prior year.
* Order Backlog: Reached $49.3 million.
* Key Drivers: Robust demand from the automotive/electric vehicle and defense/aerospace sectors.

Company management attributed the quarter’s revenue shortfall to technical issues that delayed the completion and shipment of several systems, amounting to approximately $2 million. They confirmed these issues have since been resolved and the delayed systems have been delivered to customers.

Quarterly Results Trigger Market Sell-Off

The initial figures from the third quarter were undeniably sobering for the market. Revenue of $26.2 million missed analyst forecasts of $29.09 million by nearly 10%. The situation was more severe on the bottom line; instead of the anticipated adjusted earnings of 3 to 4 cents per share, the company reported a loss of 2 cents per share.

Should investors sell immediately? Or is it worth buying inTest?

The market’s reaction was swift and severe. The stock plummeted over a two-day selling frenzy. It first fell 3.7% in pre-market trading, followed by a daily loss of 6.94% to close at $8.05. The downward trend continued the next day, with shares dropping another 6.42% to settle at $7.72. Cumulatively, this represented a loss exceeding 13% in just 48 hours.

Advertisement:

For those interested in turnaround opportunities like inTest – a complimentary report highlights three tech stocks with significant comeback potential. Download the Tech Comeback Report Now

Analyst Confidence and Future Outlook

Can the stock recover from this setback? The signs are not unfavorable. Lake Street Capital Markets expressed continued confidence, raising its price target from $8 to $10 while maintaining a “Buy” rating. The average analyst price target stands at $10, suggesting substantial upside potential from the current level around $7.72.

Looking ahead, the company’s own guidance for the fourth quarter anticipates a recovery, with projected revenues between $30 and $32 million. From a technical perspective, chart support levels are identified around $7.10 and $7.00. The next major test for the company will come in February 2026 with the release of its full-year financial results.

Ad

inTest Stock: Buy or Sell?! New inTest Analysis from November 8 delivers the answer:

The latest inTest figures speak for themselves: Urgent action needed for inTest investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 8.

inTest: Buy or sell? Read more here...

Tags: inTest
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Minervaeurosciences Stock
Earnings

A Critical Year Ahead for Minerva Neurosciences

November 8, 2025
Scynexis Stock
Earnings

Scynexis at a Crossroads: Can a GSK Deal Reverse Its Fortunes?

November 8, 2025
Quantum Computing Stock
AI & Quantum Computing

Quantum Computing Stock Plummets Amidst Financial Turmoil

November 8, 2025
Next Post
Bitcoin Stock

Bitcoin Plunges to Lowest Level in a Year Amid Divergent Investor Sentiment

Diginex Stock

Diginex Accelerates Growth Strategy with Edge AI Acquisition

Metaplanet Stock

Metaplanet Accelerates Bitcoin Acquisition Strategy with Major Debt Financing

Recommended

Seres Therapeutics Stock

Biotech Firm Seres Therapeutics Navigates Critical Restructuring Phase

4 weeks ago
Provident Services Stock

Institutional Investment Fuels Provident Financial Services Shares

2 months ago
Autohome Stock

Leadership Reshuffle at Autohome Signals Strategic Shift

2 months ago
Bristol-Myers Squibb Stock

Bristol-Myers Squibb’s Alzheimer’s Therapy Gains Momentum as Investors Weigh Pipeline Against Patent Cliff

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

A Critical Year Ahead for Minerva Neurosciences

Scynexis at a Crossroads: Can a GSK Deal Reverse Its Fortunes?

Redcare Pharmacy Shares Plunge Despite Strong Fundamentals

Quantum Computing Stock Plummets Amidst Financial Turmoil

Apyx Medical Shares Surge on Strong Quarterly Results

CorVel’s AI Strategy Faces Market Valuation Test

Trending

Trinity Biotech Stock
Analysis

Trinity Biotech Shares Face Persistent Downward Pressure

by Andreas Sommer
November 8, 2025
0

Trinity Biotech's stock continues to navigate challenging market conditions as bearish signals dominate the technical landscape. The...

I-Mab Stock

NovaBridge Biosciences Unveils Promising Clinical Trial Data and Strategic Rebranding

November 8, 2025
US Energy Stock

US Energy’s Pivotal Moment: Navigating Financial Headwinds with Ambitious Strategy

November 8, 2025
Minervaeurosciences Stock

A Critical Year Ahead for Minerva Neurosciences

November 8, 2025
Scynexis Stock

Scynexis at a Crossroads: Can a GSK Deal Reverse Its Fortunes?

November 8, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Trinity Biotech Shares Face Persistent Downward Pressure
  • NovaBridge Biosciences Unveils Promising Clinical Trial Data and Strategic Rebranding
  • US Energy’s Pivotal Moment: Navigating Financial Headwinds with Ambitious Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com